NCT06538038 2026-03-16
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
PrECOG, LLC.
Recruiting
PrECOG, LLC.
Bristol-Myers Squibb
Qianfoshan Hospital
Aetion, Inc.
Aetion, Inc.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Xiangya Hospital of Central South University
European Lung Cancer Working Party
Sungkyunkwan University
Eli Lilly and Company
Eli Lilly and Company